Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Shared-Decision Making for Hydroxyurea

The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into

hydroxyurea
  • 59 views
  • 27 Jan, 2021
  • 8 locations
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

"Pharmacokinetics and Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia" (NCT01506544) trial. Exploratory Objectives: Capture information regarding

anemia
body mass index
hydroxyurea oral capsule
hydroxyurea
schwartz
  • 35 views
  • 19 Mar, 2021
  • 1 location
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial

affects African Americans and other underserved communities. Hydroxyurea (HU) is the sole FDA-approved drug therapy for SCD and is highly effective and improves quality of life. The proposed study, a 5

sickle hemoglobin
blood disorder
thalassemia
hydroxyurea
  • 6 views
  • 23 Jan, 2021
  • 3 locations
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

RATIONALE: Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing

  • 17 views
  • 07 Nov, 2020
  • 1 location
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization

This project proposes to develop, test and evaluate targeted interventions to improve clinical provider prescribing of and patient adherence to hydroxyurea (HU). Using a stepped-wedge design

sickle hemoglobin
hemoglobin s
thalassemia
hydroxyurea
  • 3 views
  • 09 May, 2021
  • 8 locations
Therapeutic Response Evaluation and Adherence Trial (TREAT)

The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics model

anemia
thalassemia
hydroxyurea
  • 20 views
  • 26 Jan, 2021
  • 1 location
EXTEND EXpanding Treatment for Existing Neurological Disease

The primary goal of the Phase II EXTEND trial is to investigate the effects of open-label hydroxyurea treatment, escalated to maximum tolerated dose, for children with Sickle Cell Anemia and

stroke
anemia
thalassemia
hydroxyurea
transcranial doppler ultrasonography
  • 19 views
  • 22 Feb, 2021
  • 1 location
Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabine, thiotepa, anti-thymocyte globulin, and cyclophosphamide. It also includes radiation.

stroke
iron overload
preparative regimen
cyclophosphamide
iron
  • 33 views
  • 13 Feb, 2021
  • 1 location
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

from hydroxyurea therapy. Fully HLA matched siblings will be used as donors for hematopoietic stem cells to reduce the risk of morbidity and mortality in this cohort of patients.

stroke
acute chest syndrome
hypertension
alloimmunization
hydroxyurea
  • 28 views
  • 28 Jan, 2021
  • 1 location
Tagraxofusp (SL-401) in Patients With CMML or MF

(MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive

thrombocytosis
myelomonocytic leukemia
chronic myelomonocytic leukemia
platelet count
hydroxyurea
  • 145 views
  • 24 Jan, 2021
  • 13 locations